A detailed history of Jacob Asset Management Of New York LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Jacob Asset Management Of New York LLC holds 4,850 shares of APLS stock, worth $161,602. This represents 0.26% of its overall portfolio holdings.

Number of Shares
4,850
Previous 434 1017.51%
Holding current value
$161,602
Previous $39,000 371.79%
% of portfolio
0.26%
Previous 0.04%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 01, 2023

BUY
$23.65 - $89.22 $104,438 - $393,995
4,416 Added 1017.51%
4,850 $184,000
Q2 2023

Aug 10, 2023

SELL
$76.68 - $93.31 $8,434 - $10,264
-110 Reduced 20.22%
434 $39,000
Q1 2023

May 11, 2023

SELL
$46.59 - $66.96 $163,065 - $234,359
-3,500 Reduced 86.55%
544 $35,000
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $59,887 - $84,540
1,385 Added 52.09%
4,044 $209,000
Q3 2022

Nov 10, 2022

BUY
$44.76 - $69.66 $44,983 - $70,008
1,005 Added 60.76%
2,659 $182,000
Q2 2022

Aug 11, 2022

SELL
$35.07 - $59.21 $57,690 - $97,400
-1,645 Reduced 49.86%
1,654 $75,000
Q1 2022

May 12, 2022

SELL
$35.46 - $54.12 $338,855 - $517,170
-9,556 Reduced 74.34%
3,299 $168,000
Q4 2021

Feb 09, 2022

SELL
$30.74 - $49.16 $99,382 - $158,934
-3,233 Reduced 20.1%
12,855 $608,000
Q3 2021

Nov 12, 2021

BUY
$31.4 - $69.84 $90,683 - $201,697
2,888 Added 21.88%
16,088 $530,000
Q2 2021

Oct 04, 2021

BUY
$40.9 - $64.9 $130,880 - $207,680
3,200 Added 32.0%
13,200 $834,000
Q4 2020

Oct 04, 2021

BUY
$30.79 - $57.2 $307,900 - $572,000
10,000 New
10,000 $572,000

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.66B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Jacob Asset Management Of New York LLC Portfolio

Follow Jacob Asset Management Of New York LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacob Asset Management Of New York LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jacob Asset Management Of New York LLC with notifications on news.